| Biomarker ID | 856 |
| PMID | 22298030 |
| Year | 2012 |
| Biomarker | miR-940 |
| Biomarker Basis | Expression Based |
| Biomolecule | miRNA |
| Source | Plasma |
| Subjects | Humans |
| Regulation | Upregulated in PCa |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include:-mintracellular transport;Golgi apparatus; cell junction; synapse; Golgi membrane |
| Experiment | prostate cancer Vs benign prostatic hyperplasia |
| Type of Biomarker | Diagnostic |
| Cohort | Training set: 25 patients with prostate cancer, 17 with Benign prostatic hyperplasia. Validation Set: 80 CaP, 44 BPH, and 54 healthy controls |
| Senstivity | 90% |
| Specificity | 62.96% |
| AUC | 0.791 (95% CI: 0.709–0.872) |
| Accuracy | NA |
| Level Of Significance | Training: p= 0.0062 |
| Method Used | Training Set: Microarrays, Validation set; qRT-PCR |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on Independent Patient Cohort |
| Technical Name | miR-940 |